21148 ⎘
Medicinal preparations containing antigens or antibodies; Antibodies ; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
Sub-classes:Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
#2NEUTRALIZING ANTI-TL1A MONOCLONAL ANTIBODIES
#3ISOFORM-SELECTIVE ANTI-TGF-BETA ANTIBODIES AND METHODS OF USE
#4METHOD OF ASSESSING ANTI-PRURITIC ACTIVITY OF A CANINE ANTI-IL-31 ANTIBODY CANDIDATE
#5FORMULATIONS WITH REDUCED OXIDATION
#6COMPOSITIONS AND METHODS FOR ENHANCING TRIPLEX AND NUCLEASE-BASED GENE EDITING
#7ANTI-CD16A ANTIBODIES AND METHODS OF USE THEREOF
#8ANTIBODIES DIRECTED AGAINST INTERLEUKIN 36 RECEPTOR (IL-36R)
#9USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK)
#10COMPOSITIONS AND METHODS FOR BLOOD-BRAIN BARRIER DELIVERY
#11MONOCLONAL ANTIBODIES TO GROWTH AND DIFFERENTIATION FACTOR 15 (GDF-15), AND USES THEREOF FOR TREATING CANCER CACHEXIA AND CANCER
#12COMBINATION THERAPY USING AN ANTI-FUCOSYL-GM1 ANTIBODY AND AN ANTI-CD137 ANTIBODY
#13MITIGATING TISSUE DAMAGE AND FIBROSIS VIA LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN (LTBP4)
#14IMMUNE CHECKPOINT INHIBITOR COMBINATIONS
#15ANTI-GDF15 ANTIBODIES, COMPOSITIONS AND METHODS OF USE
#16CONNEXIN 43 ANTIBODIES AND USE THEREOF
#17METHOD OF USING AN ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) ACTIVATABLE ANTIBODY TO DETECT THE PRESENCE OR ABSENCE OF A CLEAVING AGENT AND EGFR
#18Anti-NGF Antibodies and Methods Thereof
#19Anti-NGF Antibodies and Methods Thereof
#20ANTI-FLT3 ANTIBODIES AND COMPOSITIONS
#21METHODS RELATED TO ADMINISTERING IMMUNOSUPPRESSANTS AND THERAPEUTIC MACROMOLECULES AT A REDUCED PHARMACODYNAMICALLY EFFECTIVE DOSE
#22ANTIBODY FORMULATION
#23ANTI-NGF ANTIBODIES AND METHODS OF TREATING PAIN THEREOF
#24TREATMENT OF RENAL CELL CARCINOMA
#25HUMAN CGRP RECEPTOR BINDING PROTEINS
#26CANINE ANTI-NGF ANTIBODIES AND METHODS OF TREATING PAIN THEREOF
#27MITIGATING TISSUE DAMAGE AND FIBROSIS VIA LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN (LTBP4)
#28METHOD OF TREATING A TUMOR WITH A COMBINATION OF IL-7 PROTEIN AND VEGF ANTAGONIST
#29Arthritis Treatment
#30Antibody Variants
#31BETA-GLUCAN IMMUNOTHERAPIES AFFECTING THE IMMUNE MICROENVIRONMENT
#32ANTI-PRO/LATENT-MYOSTATIN ANTIBODIES AND USES THEREOF
#33LUNG CANCER BIOMARKERS
#34METHODS OF ADMINISTERING IMMUNOSUPPRESSANTS HAVING A SPECIFIED PHARMACODYNAMIC EFFECTIVE LIFE AND THERAPEUTIC MACROMOLECULES FOR THE INDUCTION OF IMMUNE TOLERANCE
#35ANTI-CD25 ANTIBODY AGENTS
#36Immune checkpoint inhibitor combinations
#37MITIGATING TISSUE DAMAGE AND FIBROSIS VIA LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN (LTBP4)
#38ISOFORM-SELECTIVE ANTI-TGF-BETA ANTIBODIES AND METHODS OF USE
#39COMBINATION THERAPY USING AN ANTI-FUCOSYL-GM1 ANTIBODY AND AN ANTI-CD137 ANTIBODY
#40SUBCUTANEOUSLY ADMINISTERED ANTI-IL-6 RECEPTOR ANTIBODY
#41ANTI-KIT ANTIBODIES AND USES THEREOF
#42COMBINATION THERAPY USING AN ANTI-FUCOSYL-GM1 ANTIBODY AND AN ANTI-CD137 ANTIBODY
#43ANTIBODY THAT BINDS TO VEGF AND IL-1BETA AND METHODS OF USE
#44Anti-Tumor Immunotherapy Enhancer
#45NANOPARTICLE COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY
#46MULTIVALENT BINDING MOLECULES
#47HETEROCYCLIC COMPOUNDS AND USES THEREOF
#48GENETICALLY MODIFIED HUMAN NATURAL KILLER CELL LINES
#49COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1 AND/OR PD-L1 INHIBITOR
#50Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
#51MONOCLONAL ANTIBODIES TO GROWTH AND DIFFERENTIATION FACTOR 15 (GDF-15), AND USESTHEREOF FOR TREATING CANCER CACHEXIA AND CANCER
#52NEUTRALIZING ANTI-TL1A MONOCLONAL ANTIBODIES
#53GENETICALLY MODIFIED HUMAN NATURAL KILLER CELL LINES
#54NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWIS A
#55THERAPIES AND METHODS TO TREAT TLR2-MEDIATED DISEASES AND DISORDERS
#56miR-3132 upregulation of the trail pathway and apoptotic activity in cancer cells
#57METHOD FOR TREATING A GD2 POSITIVE CANCER
#58QUINAZOLINE-DERIVED HCK INHIBITORS FOR USE IN THE TREATMENT OF MYD88 MUTATED DISEASES
#59PRODRUGGABLE ANTIBODIES, PRODRUGS THEREOF, AND METHODS OF USE AND MAKING
#60NATURAL ANTIBODIES IN PROPHYLAXIS AND THERAPY
#61USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK)
#62COMPOSITIONS AND METHODS FOR ENHANCING TRIPLEX AND NUCLEASE-BASED GENE EDITING
#63Fully humanized anti-platelet factor 4 antibodies that treat heparin-induced thrombocytopenia
#64USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK)
#65MODULATING IMMUNE RESPONSE
#66MITIGATING TISSUE DAMAGE AND FIBROSIS VIA LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN (LTBP4)
#67INHIBITION OF BMI1 ELIMINATES CANCER STEM CELLS AND ACTIVATES ANTITUMOR IMMUNITY
#68ANTI-PAD2 ANTIBODY FOR TREATING AND EVALUATING AUTOIMMUNE AND INFLAMMATORY DISEASES
#69IMMUNE CHECKPOINT INHIBITOR COMBINATIONS
#70Subcutaneously administered anti-IL-6 receptor antibody
#71FORMULATIONS WITH REDUCED OXIDATION
#72METHODS AND MATERIALS FOR TREATING NEUROMYELITIS OPTICA SPECTRUM DISEASES
#73Compositions and Methods For Blood-Brain Barrier Delivery
#74BETA-GLUCAN IMMUNOTHERAPIES AFFECTING THE IMMUNE MICROENVIRONMENT
#75DAMAGE-TARGETED TREATMENTS OF DISEASE
#76IMMUNOGLOBULIN SINGLE DOMAIN ANTIBODIES FOR DELIVERY OF MUCOSAL VACCINES
#77ANTIBODY MOLECULES TO CD73 AND USES THEREOF
#78METHODS PROVIDING A THERAPEUTIC MACROMOLECULE AND SYNTHETIC NANOCARRIERS COMPRISING IMMUNOSUPPRESSANT LOCALLY AND CONCOMITANTLY TO REDUCE BOTH TYPE 1 AND TYPE IV HYPERSENSITIVITY
#79Anti-GDF15 antibodies, compositions and methods of use
#80Arthritis treatment
#81HUMAN ANTIBODIES AND ANTIBODY-DRUG CONJUGATES AGAINST CD74
#82ANTI-OPIOID COMPOUNDS AND METHODS OF MAKING AND USING SAME
#83Method of using an anti-epidermal growth factor receptor (EGFR) activatable antibody to detect the presence or absence of a cleaving agent and EGFR
#84METHODS FOR THE TREATMENT OF CANCER
#85Subcutaneously administered anti-IL-6 receptor antibody
#86Therapeutic use of levorotatory β-lactams in hematopoiesis, immuno-oncology therapy, and regulation of lipoprotein and apolipoprotein levels
#87USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK)
#88Immunogen for Preventing or Treating Familial Frontotemporal Dementia (FTD) and/or Amyotrophic Lateral Sclerosis (ALS)
#89Methods for Treating Osteogenesis Imperfecta
#90USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK)
#91Compositions for making and using anti-Myostatin antibodies
#92TREATMENT OF NEONATAL HYPOXIA INCLUDING IMPAIRMENTS OR EFFECTS THEREOF
#93TECHNIQUES FOR PREDICTING, DETECTING AND REDUCING ASPECIFIC PROTEIN INTERFERENCE IN ASSAYS INVOLVING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS
#94METHODS FOR TREATING GI SYNDROME AND GRAFT VERSUS HOST DISEASE
#95BETA-GLUCAN IMMUNOTHERAPIES AFFECTING THE IMMUNE MICROENVIRONMENT
#96miR-3132 upregulation of the TRAIL pathway and apoptotic activity in cancer cells
#97MITIGATING TISSUE DAMAGE AND FIBROSIS VIA LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN (LTBP4)
#98COMPOSITIONS COMPRISING ANTI-CD38 ANTIBODIES AND CARFILZOMIB
#99Therapeutic Cell Systems and Methods for Treating Cancer and Infectious Diseases
#100ANTI-CD40 BINDING MOLECULES HAVING ENGINEERED FC DOMAINS AND THERAPEUTIC USES THEREOF
#101METHODS OF ADMINISTERING IMMUNOSUPPRESSANTS HAVING A SPECIFIED PHARMACODYNAMIC EFFECTIVE LIFE AND THERAPEUTIC MACROMOLECULES FOR THE INDUCTION OF IMMUNE TOLERANCE
#102Antibody that binds to VEGF and IL-1beta and methods of use
#103IL-2 muteins and uses thereof
#104Anti-kit antibodies and uses thereof
#105METHODS AND COMPOSITIONS FOR THE TREATMENT AND/OR PREVENTION OF TYPE 1 DIABETES
#106Treatment of renal cell carcinoma
#107IMMUNE CHECKPOINT INHIBITOR COMBINATIONS
#108Preparation and use of anti-MET-and-RON bispecific antibody and antibody-drug conjugate thereof
#109ANTIBODIES DIRECTED AGAINST INTERLEUKIN 36 RECEPTOR (IL-36R)
#110METHOD OF TREATING PRIMARY SCLEROSING CHOLANGITIS
#111COMBINATION THERAPY USING AN ANTI-FUCOSYL-GM1 ANTIBODY AND AN ANTI-CD137 ANTIBODY
#112Methods of treating solid tumors with CCR2 antagonists
#113COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY
#114COMPOSITIONS AND METHODS FOR ENHANCING TRIPLEX AND NUCLEASE-BASED GENE EDITING
#115Anti-FLT3 antibodies and compositions
#116Anti-CD40 antibody having engineered Fc domains and therapeutic uses thereof
#117Isoform-selective anti-TGFβ antibodies and methods of use
#118Compositions and methods for treating Crohn's Disease and related conditions and infections
#119CANCER TARGETS AND USES THEREOF
#120Anti-BAFFR antibody formulations and methods of use thereof
#121COMBINATION OF A TYPE II PROTEIN ARGININE METHYLTRANSFERASE INHIBITOR AND AN ICOS BINDING PROTEIN TO TREAT CANCER
#122Combination Therapies and Uses for Treatment of Demyelinating Disorders
#123COMBINED THERAPY WITH ICOS BINDING PROTEINS AND ARGININEMETHYLTRANSFERASE INHIBITORS
#124Envenomation therapies and related pharmaceutical compositions, systems and kits
#125CILIA-TARGETING NANOPARTICLES
#126MIR-3132 UPREGULATION OF THE TRAIL PATHWAY AND APOPTOTIC ACTIVITY IN CANCER CELLS
#127Anti-NGF Antibodies and Methods Thereof
#128COMBINED USE OF GDF TRAPS AND ERYTHROPOIETIN RECEPTOR ACTIVATORS TO INCREASE RED BLOOD CELL LEVELS
#129COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING LUPUS
#130MITIGATING TISSUE DAMAGE AND FIBROSIS VIA LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN (LTBP4)
#131SUBCUTANEOUSLY ADMINISTERED ANTI-IL-6 RECEPTOR ANTIBODY
#132Anti-NGF Antibodies and Methods Thereof
#133Canine anti-NGF antibodies and methods of treating pain thereof
#134Felinized anti-NGF antibodies and methods of treating pain
#135Anti-NGF Antibodies and Methods Thereof
#136Methods of treating a canine and inhibiting NGF activity through use of anti-NGF antibodies
#137Conjugate vaccine targeting a disease-causing biological protein
#138Humanized anti-NGF antibodies and methods of treating pain thereof
#139Nucleic acids encoding a canine antibody which binds nerve growth factor and vectors and host cells thereof
#140Human CGRP receptor binding proteins
#141Human CGRP receptor binding proteins
#142Use of toll-like receptor agonist for treating cancer
#143Use of inhibitors of Brutons tyrosine kinase (Btk)
#144Connexin 43 antibodies and use thereof
#145Therapies and methods to treat TLR2-mediated diseases and disorders
#146RADIOIMMUNOCONJUGATES IN COMBINATION WITH OTHER DRUGS AS TREATMENT AGAINST NHL
#147NEUTRALIZING ANTI-TL1A MONOCLONAL ANTIBODIES
#148Ichthyophthirius multifiliis vaccine system
#149Polycyclic carbamoylpyridone derivatives, pharmaceutical compositions and use thereof
#150Cyclic compound/peptide comprising an A-beta13-16 peptide and a linker that is covalently coupled to the n-terminus residue and the c-terminus residue of the A-beta13-16 peptide
#151Cyclic compound/peptide comprising an A-beta15-18 peptide and a linker that is covalently coupled to the n-terminus residue and the c-terminus residue of the A-BETA15-18 peptide
#152SYNTHETIC VACCINE
#153PHARMACEUTICAL FORMULATIONS
#154COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY
#155Anti-CD25 antibody agents
#156Anti-CD25 for tumour specific cell depletion
#157Anti-CD25 for tumour specific cell depletion
#158Compositions comprising cyclic peptides derived from an A-beta peptide
#159Methods of Treating Antibody-Mediated Disorders with FcRn Antagonists
#160Factor IX polypeptides and methods of use thereof
#161Anti-CD25 for tumour specific cell depletion
#162Anti-CD25 for tumour specific cell depletion
#163Anti-CD25 for tumour specific cell depletion
#164Anti-CD25 antibody agents
#165FACTOR IX POLYPEPTIDES AND METHODS OF USE THEREOF
#166Multivalent binding molecules
#167Heterocyclic compounds and uses thereof
#168Anti-CD25 antibody agents
#169Antagonist antibodies that bind to human TGFB1, TGFB2 and to TGFB3 and their use for the treatment of lung fibrosis
#170Compositions and methods for treating ovarian tumors
#171MITIGATING TISSUE DAMAGE AND FIBROSIS VIA LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN (LTBP4)
#172NOVEL ANTI-HUMAN GPVI ANTIBODIES AND USES THEREOF
#173Anti-tumor immunotherapy enhancer
#174Therapeutic use of levorotatory β-lactams in hematopoiesis, immuno-oncology therapy, and regulation of lipoprotein and apolipoprotein levels
#175BSL2v2c2-Ig POLYPEPTIDES
#176COMPOSITIONS AND METHODS FOR REDUCING LOCAL AND SYSTEMIC RISKS OF ENVENOMATION
#177TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE OR PREVENT ANAPHYLAXIS IN RESPONSE TO A NON-ALLERGENIC ANTIGEN
#178TETRAVALENT TLR9 BISPECIFIC ANTIBODY
#179Methods for treating heart failure using glucagon receptor antagonistic antibodies
#180COMPOSITIONS AND METHODS RELATED TO CELL SYSTEMS FOR PENETRATING SOLID TUMORS
#181Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
#182Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia and cancer
#183Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia and cancer
#184Nanoparticle compositions and methods for immunotherapy
#185Combination Therapy Using a Chemokine Receptor 2 (CCR2) Antagonist and a PD-1 and/or PD-L1 Inhibitor
#186Targeted protein degradation
#187ANTI-EGFR ANTIBODY DRUG CONJUGATE FORMULATIONS
#188Antibody variants
#189Combination Therapies and Uses for Treatment of Demyelinating Disorders
#190Method of treating or delaying progression of an epidermal growth factor receptor (EGFR)-related disorder by administering activatable EGFR-binding antibodies
#191ANTIBODIES AGAINST PHOSPHORYLCHOLINE IN COMBINATION THERAPY WITH BIOLOGIC AGENTS
#192METHODS FOR TREATING HIGH CARDIOVASCULAR RISK PATIENTS WITH HYPERCHOLESTEROLEMIA
#193Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
#194NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWIS A
#195COMPOSITIONS AND METHODS INCLUDING A RECOMBINANT HUMAN MAB THAT PROMOTES CNS REMYELINATION
#196Compositions and methods for inhibiting arginase activity
#197Antibody that binds to VEGF and IL-1beta and methods of use
#198Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
#199Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels
#200Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels
#201Fully humanized anti-platelet factor 4 antibodies that treat heparin-induced thrombocytopenia
#202Use of inhibitors of Bruton's tyrosine kinase (Btk)
#203LUNG CANCER BIOMARKERS
#204MITIGATING TISSUE DAMAGE AND FIBROSIS VIA LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN (LTBP4)
#205Treatment of fibrodysplasia ossificans progressiva
#206METHODS RELATED TO ADMINISTERING IMMUNOSUPPRESSANTS AND THERAPEUTIC MACROMOLECULES AT A REDUCED PHARMACODYNAMICALLY EFFECTIVE DOSE
#207Compositions and methods for in vitro activation and expansion of serial killer T cell populations and passive immunization of a cancer patient with tumor cell killing cells
#208Method of treating pustular psoriasis with antibodies directed against interleukin 36 receptor (IL-36R)
#209Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both type I and type IV hypersensitivity
#210Inhibitors of prototypic galectin dimerization and uses thereof
#211METHODS COMPRISING DOSING COMBINATIONS FOR REDUCING UNDESIRED HUMORAL IMMUNE RESPONSES
#212METHODS OF ADMINISTERING IMMUNOSUPPRESSANTS HAVING A SPECIFIED PHARMACODYNAMIC EFFECTIVE LIFE AND THERAPEUTIC MACROMOLECULES FOR THE INDUCTION OF IMMUNE TOLERANCE
#213Method for Treating a GD2 Positive Cancer
#214Human antibodies to GFRα3 and methods of making thereof
#215FOXC1 ANTIBODIES AND METHODS OF THEIR USE
#216Therapeutic use of tromethamine salt of L-ampicilline in hematopoiesis, immuno-oncology therapy, and regulation of lipoprotein and apolipoprotein levels
#217Methods for treating osteogenesis imperfecta
#218Methods for making and using anti-myostatin antibodies
#219Use of inhibitors of bruton's tyrosine kinase (BTK)
#220Antagonist antibodies that bind to human TGFB1, TGFB2 and to TGFB3 and their use for the treatment of lung fibrosis
#221SELECTIVE REMOVAL OF AGE-MODIFIED CELLS FOR TREATMENT OF ATHEROSCLEROSIS
#222Peptide-Mediated Non-Covalent Delivery of Active Agents Across the Blood-Brain Barrier
#223COMPOSITIONS COMPRISING ANTI-CD38 ANTIBODIES AND CARFILZOMIB
#224IL-2 muteins and uses thereof
#225Therapeutic cell systems and methods for treating cancer and infectious diseases
#226Anti-NGF antibodies and methods thereof
#227Use of toll-like receptor agonist for treating cancer
#228Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels
#229Mitigating Tissue Damage and Fibrosis Via Latent Transforming Growth Factor Beta Binding Protein (LTBP4)
#230BSL2v2c2-Ig polypeptides
#231Compositions and methods for treating Crohn's disease and related conditions and infections
#232NEUTRALIZING ANTI-TL1A MONOCLONAL ANTIBODIES
#233Subcutaneously administered anti-IL-6 receptor antibody
#234Anti-BAFFR antibody formulations and methods of use thereof
#235Factor IX polypeptides and methods of use thereof
#236Factor IX polypeptides and methods of use thereof
#237TrkB agonist antibodies and methods for treating an ocular degenerative disorder characterized by degeneration of retinal ganglion cells (RGCs)
#238Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
#239CANCER TREATMENT PHARMACEUTICAL COMPOSITION USING ANTI-MCT5 ANTIBODY
#240Co-activation of mTOR and STAT3 pathways to promote neuronal survival and regeneration
#241Combination therapy using an anti-fucosyl-GM1 antibody and an anti-CD137 antibody
#242Methods of treating by administering anti-kit antibodies
#243Conjugate vaccine targeting a disease-causing biological protein
#244Stable aqueous formulations of adalimumab
#245Stable aqueous formulations of adalimumab
#246Stable aqueous formulations of adalimumab
#247EPITOPE MIMICS
#248Stable aqueous formulations of adalimumab
#249Prodruggable antibodies, prodrugs thereof, and methods of use and making
#250Antibody molecules to CD73 and uses thereof
#251Nanoparticle compositions and methods for immunotherapy
#252BETA-GLUCAN IMMUNOTHERAPIES AFFECTING THE IMMUNE MICROENVIRONMENT
#253Targeted protein degradation
#254MITIGATING TISSUE DAMAGE AND FIBROSIS VIA LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN (LTBP4)
#255IG1 AND THE THERAPEUTIC USE THEREOF
#256Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
#257Compositions and methods for inhibiting arginase activity
#258Use of toll-like receptor agonist for treating cancer
#259Compositions and methods for treating or preventing lupus
#260Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
#261Formulations with reduced oxidation
#262METHODS FOR TREATING REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS
#263Stable aqueous formulations of adalimumab
#264Stable aqueous formulations of adalimumab
#265Stable aqueous formulations of adalimumab
#266Stable aqueous formulations of adalimumab
#267Anti-Tie2 antibodies and uses thereof
#268Methods for treating cancer using PS-targeting antibodies with immuno-oncology agents
#269ANTI-PAD2 ANTIBODY FOR TREATING AND EVALUATING RHEUMATOID ARTHRITIS
#270USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK)
#271Immune checkpoint inhibitor combinations
#272Specific interleukin-15 (IL-15) antagonist polypeptide and uses thereof for the treatment of inflammatory and auto-immune diseases
#273Methods for treating heart failure using glucagon receptor antagonistic antibodies
#274Stimulation of ovarian follicle development and oocyte maturation
#275Use of inhibitors of bruton's tyrosine kinase (Btk)
#276Anti-human GPVI antibodies and uses thereof
#277Factor IX Polypeptides and Methods of Use Thereof
#278Factor IX polypeptides and methods of use thereof
#279Methods and compositions for modulation of blood-neural barrier
#280Combined use of anti PD-1 and anti M-CSF antibodies in the treatment of cancer
#281Pharmaceutical composition containing the tromethamine salt of L-ampicillin
#282Factor IX Polypeptides and Methods of Use Thereof
#283In vivo Imaging using Anti-IL-6 Antibodies
#284Process for immobilizing one or more receptor biomolecules on one or more solid surfaces
#285Antibodies against phosphorylcholine in combination therapy with biologic agents
#286Treatment for myopathy
#287ANTIBODY FORMULATION
#288Compositions and Methods including a Recombinant Human MAB that Promotes CNS Remyelination
#289Treatment of renal cell carcinoma
#290Inhibitors of prototypic galectin dimerization and uses thereof
#291CANCER TARGETS AND USES THEREOF
#292COMPOSITIONS AND METHODS RELATED TO CELL SYSTEMS FOR PENETRATING SOLID TUMORS
#293Antibodies against phosphorylcholine in combination therapy with biologic agents
#294Anti-human NGF antibody Fab fragment and methods for treating postoperative pain related to NGF
#295HUMAN CGRP RECEPTOR BINDING PROTEINS
#296Stable aqueous formulations of adalimumab
#297Method for treating a GD2 positive cancer
#298NOVEL IMMUNOMODULATORY THERAPEUTIC STRATEGIES TARGETING TUMORS IN CANCER
#299Treatment of Fibrodysplasia Ossificans Progressiva
#300Neutralizing anti-TL1A monoclonal antibodies